Investigational Drug Details
Drug ID: | D143 |
Drug Name: | FT-4101 |
Synonyms: | -- |
Type: | Miscellany |
DrugBank ID: | -- |
DrugBank Description: | -- |
PubChem ID: | -- |
CasNo: | -- |
Repositioning for NAFLD: | No |
SMILES: | -- |
InChiKey: | -- |
Molecular Weight: | -- |
DrugBank Targets: | -- |
DrugBank MoA: | -- |
DrugBank Pharmacology: | -- |
DrugBank Indication: | -- |
Targets: | FASN inhibitor |
Therapeutic Category: | Enhance lipid metabolism |
Clinical Trial Progress: | Phase 1&2 terminated (NCT04004325: sponsor decision) |
Latest Progress: | Under clinical trials |

Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
---|---|---|---|---|---|---|---|
L0464 | NCT04004325 | Phase 1/Phase 2 | Not recruiting | No Results Available | 10/06/2019 | 25 January 2021 | Details |
Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
---|---|---|---|---|---|
S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |